Abstract: This invention relates to preparations derived from amniotic fluid, and more specifically, to an amniotic fluid preparation with specific standardized measure of the biologic activity of a component of the preparation, such as a constituent protein, for use in clinical and research applications. The amniotic fluid preparation with standardized biologic activity resolves problems of establishing efficacy, safety, and reproducibility in the clinical and investigatory use of amniotic fluid-derived preparations for the treatment of a wide range of degenerative illnesses, traumatic injuries, tissue and organ transplantation, and other medical conditions.

Abstract: The invention relates to an amniotic fluid-derived preparation. The amniotic fluid-derived preparation leverages cellular and non-cellular constituent components of amniotic fluid for use across a broad range of therapeutic applications, including use by physicians and other healthcare providers in the surgical and minimally invasive medical therapy of a wide range of injuries and disease processes. The amniotic fluid-derived preparation concentrates available quantities of non-cellular bioactive proteins and cellular elements to enhance therapeutic efficacy in multiple clinical settings. The amniotic fluid-derived preparation may be intraoperatively transplanted at the recipient site using a needleless syringe, by non-operative percutaneous injection through a hypodermic needle, or by direct application.

Abstract: The invention relates to methods of forming derivatives of amniotic fluid. Specifically, embodiments of the disclosed invention relate to methods of forming amniotic fluid-derived preparations from donor amniotic fluid for use in clinical medicine and medical research.

Abstract: The invention relates to preparations of amniotic membrane-derived tissue grafts standardized for the concentration amniotic membrane and its constituent components by dry weight. The standardized amniotic membrane tissue graft is used by physicians and other healthcare providers in the surgical and minimally invasive medical therapy of a wide range of injuries and disease processes. The preparations maximize available quantities of non-cellular bioactive compounds and viscosity to enhance therapeutic efficacy for the desired application. The standardized amniotic membrane tissue graft preparations are semi-viscous fluids or gels which may be intraoperatively transplanted at the recipient site using a needless syringe, by non-operative percutaneous injection through a hypodermic needle, or by direct application.

Abstract: The invention relates to preparations and methods of creating preparations of reconstituted amniotic membrane denuded of the amniocyte/epithelial cell layer to preserve amniocytes viability during processing. The tissue graft utilizes amniotic fluid as a source of additional viable stem cells. The amniotic tissue graft is flowable and injectable, and designed for use in surgical and minimally invasive medical therapy of injury and disease to promote tissue regeneration and healing. The tissue grafts optimize available quantities of viable mesenchymal stem cells and non-cellular bioactive compounds to enhance therapeutic efficacy. The tissue grafts are semi-viscous fluids which may be intraoperatively transplanted at the recipient site using a needless syringe or by non-operative percutaneous injection through a hypodermic needle.

Abstract: The invention relates to an injectable amniotic membrane tissue graft product for percutaneous, minimally invasive, surgical, and topical therapy of injury and disease and methods of applying such tissue grafts to a subject at a particular location. The injectable preparations maximize and standardize available quantities of non-cellular biological compounds to enhance therapeutic efficacy. The tissue graft preparations are semi-viscous fluids with standardized properties which may be intraoperatively transplanted at the recipient site using a needless syringe, by non-operative percutaneous injection through a hypodermic needle, or direct topical application to open cutaneous wounds and external soft tissue defects.

Abstract: The invention relates to preparations and methods of creating preparations of reconstituted amniotic membrane utilizing amniotic fluid, for use as combination tissue grafts in surgical and minimally invasive medical therapy of injury and disease. The preparations maximize available quantities of viable mesenchymal stem cells and non-cellular bioactive compounds to enhance therapeutic efficacy. The tissue graft preparations are liquids and/or semi-viscous fluids which may be intraoperatively transplanted at the recipient site using a needless syringe or by non-operative percutaneous injection through a hypodermic needle.

Abstract: The invention relates to preparations and methods of creating preparations of reconstituted amniotic membrane utilizing amniotic fluid, for use as combination tissue grafts in surgical and minimally invasive medical therapy of injury and disease. The preparations maximize available quantities of viable mesenchymal stem cells and non-cellular bioactive compounds to enhance therapeutic efficacy. The tissue graft preparations are semi-viscous fluids which may be intraoperatively transplanted at the recipient site using a needless syringe or by non-operative percutaneous injection through a hypodermic needle.

Abstract: A system for producing, stabilizing, and concentrating tri-atomic hydrogen includes a source of liquid hydrogen in the form of para-hydrogen, a piping system through which the liquid hydrogen flows, an injection point for combining the liquid hydrogen in the form of para-hydrogen with third hydrogen atoms all with the same proton spin to form H3 all with the same net magnetic orientation, and a continuous magnetic field for maintaining the magnetic orientation. The system further has a storage tank for storing concentrated liquid H3 molecules for use as a propellant.

Abstract: A Hall effect thruster for propelling spacecraft and satellites includes at least two acceleration channels, each of the channels has a closed end and an open end, and a plurality of flux guides adjacent each of the channels. The plurality of flux guides includes an innermost flux guide, an outermost flux guide, and at least one intermediate flux guide. Each intermediate flux guide helps provide a magnetic field to each of two adjacent acceleration channels.